{"id":"lenalidomide-and-low-dose-dexamethasone","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Thrombocytopenia"},{"rate":"30-40","effect":"Anemia"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Constipation"},{"rate":"10-20","effect":"Neuropathy"},{"rate":"20-30","effect":"Infection"},{"rate":"10-20","effect":"Hyperglycemia"},{"rate":"10-20","effect":"Insomnia"},{"rate":"5-15","effect":"Venous thromboembolism"}]},"_chembl":{"chemblId":"CHEMBL848","moleculeType":"Small molecule","molecularWeight":"259.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenalidomide is an immunomodulatory agent that activates T cells and natural killer cells, inhibits angiogenesis, and directly suppresses myeloma cell proliferation. Dexamethasone, a corticosteroid, enhances these effects through anti-inflammatory mechanisms and direct cytotoxic activity against plasma cells. The combination is synergistic in treating multiple myeloma.","oneSentence":"Lenalidomide enhances immune cell activity and has anti-angiogenic and anti-proliferative effects, while dexamethasone provides anti-inflammatory and immunosuppressive activity to reduce myeloma cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:30.306Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed and relapsed/refractory)"},{"name":"Light chain myeloma"}]},"trialDetails":[{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT04328662","phase":"","title":"A Study of Ninlaro in Real World Clinical Practice in China","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-05-18","conditions":"Multiple Myeloma, Neoplasms, Plasma Cell","enrollment":482},{"nctId":"NCT02969837","phase":"PHASE2","title":"Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-07-10","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT06042725","phase":"PHASE1","title":"MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-04","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT00098475","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11-03","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":452},{"nctId":"NCT03500445","phase":"PHASE2","title":"Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-02-13","conditions":"Myeloma, Multiple Myeloma","enrollment":75},{"nctId":"NCT06087653","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"Starton Therapeutics, Inc","startDate":"2023-10-02","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT01816971","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2013-01","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":76},{"nctId":"NCT01946477","phase":"PHASE2","title":"Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-05-29","conditions":"Multiple Myeloma","enrollment":186},{"nctId":"NCT04892264","phase":"PHASE1","title":"Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2021-06-03","conditions":"Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":5},{"nctId":"NCT05665140","phase":"PHASE2, PHASE3","title":"Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"University Hopsital Schleswig Holstein Campus Lübeck","startDate":"2023-02-03","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":100},{"nctId":"NCT00482261","phase":"PHASE2","title":"A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression","status":"COMPLETED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2007-06","conditions":"Multiple Myeloma","enrollment":150},{"nctId":"NCT01093196","phase":"PHASE3","title":"Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2009-10","conditions":"Multiple Myeloma","enrollment":660},{"nctId":"NCT05641324","phase":"PHASE1","title":"A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)","status":"TERMINATED","sponsor":"Anaveon AG","startDate":"2023-02-10","conditions":"Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma","enrollment":4},{"nctId":"NCT03809780","phase":"PHASE2","title":"Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone","status":"UNKNOWN","sponsor":"Kosin University Gospel Hospital","startDate":"2019-03-11","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT02903381","phase":"PHASE2","title":"A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-10-20","conditions":"Smoldering Multiple Myeloma","enrollment":8},{"nctId":"NCT00783367","phase":"PHASE2","title":"Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2008-07","conditions":"Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma","enrollment":50},{"nctId":"NCT02336815","phase":"PHASE2","title":"Selinexor Treatment of Refractory Myeloma","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-05-26","conditions":"Multiple Myeloma","enrollment":202},{"nctId":"NCT03651128","phase":"PHASE3","title":"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":381},{"nctId":"NCT03742297","phase":"PHASE3","title":"Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2018-10-22","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":462},{"nctId":"NCT02415413","phase":"PHASE2","title":"Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2015-05","conditions":"Smoldering Multiple Myeloma","enrollment":90},{"nctId":"NCT01463670","phase":"PHASE2","title":"Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-10-28","conditions":"Multiple Myeloma","enrollment":11},{"nctId":"NCT05298683","phase":"PHASE2","title":"A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor","status":"UNKNOWN","sponsor":"Hellenic Society of Hematology","startDate":"2022-05","conditions":"Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell","enrollment":108},{"nctId":"NCT04287660","phase":"PHASE3","title":"Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2017-10-19","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT02579863","phase":"PHASE3","title":"Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-19","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT02612779","phase":"PHASE2","title":"A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-02-09","conditions":"Multiple Myeloma","enrollment":74},{"nctId":"NCT02128230","phase":"PHASE2","title":"UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2014-06-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT01155583","phase":"PHASE1, PHASE2","title":"Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2010-06","conditions":"Refractory Multiple Myeloma","enrollment":45},{"nctId":"NCT02897830","phase":"PHASE2","title":"Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma","status":"TERMINATED","sponsor":"University Hospital, Toulouse","startDate":"2016-08-05","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT01497093","phase":"PHASE1","title":"Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2012-02-15","conditions":"Multiple Myeloma","enrollment":34},{"nctId":"NCT04243109","phase":"PHASE2","title":"Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib","status":"TERMINATED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2017-02-23","conditions":"Multiple Myeloma","enrollment":6},{"nctId":"NCT02589145","phase":"PHASE1, PHASE2","title":"Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"Lymphoma","enrollment":8},{"nctId":"NCT00581919","phase":"PHASE2","title":"Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2004-02","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT00689936","phase":"PHASE3","title":"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2008-08-21","conditions":"Multiple Myeloma","enrollment":1623},{"nctId":"NCT02348528","phase":"PHASE2","title":"Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year","status":"COMPLETED","sponsor":"Celgene","startDate":"2012-09-11","conditions":"Multiple Myeloma","enrollment":65},{"nctId":"NCT00807599","phase":"PHASE2","title":"Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-12-10","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT01698801","phase":"PHASE2","title":"A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2012-10-01","conditions":"Multiple Myeloma","enrollment":26},{"nctId":"NCT01311687","phase":"PHASE3","title":"A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study","status":"COMPLETED","sponsor":"Celgene","startDate":"2011-03-11","conditions":"Multiple Myeloma","enrollment":455},{"nctId":"NCT00790842","phase":"PHASE1, PHASE2","title":"Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction","status":"TERMINATED","sponsor":"PrECOG, LLC.","startDate":"2009-01-21","conditions":"Multiple Myeloma, Plasma Cell Neoplasm","enrollment":63},{"nctId":"NCT01217957","phase":"PHASE1, PHASE2","title":"A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2010-11-22","conditions":"Multiple Myeloma","enrollment":65},{"nctId":"NCT01241292","phase":"PHASE1","title":"Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-01-14","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT01518465","phase":"PHASE2","title":"Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2012-01-09","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":13},{"nctId":"NCT01593410","phase":"PHASE2","title":"Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2010-08-01","conditions":"Multiple Myeloma","enrollment":194},{"nctId":"NCT01116193","phase":"PHASE2","title":"Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Institut de Cancérologie de la Loire","startDate":"2010-01","conditions":"Leukemia, Lymphoid, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma","enrollment":10},{"nctId":"NCT01042704","phase":"PHASE1","title":"Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"Robert Redner, MD","startDate":"2008-02","conditions":"Myeloma","enrollment":29},{"nctId":"NCT00603447","phase":"PHASE1","title":"Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-05","conditions":"Relapsed Multiple Myeloma","enrollment":84},{"nctId":"NCT01019174","phase":"PHASE1, PHASE2","title":"Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","startDate":"2009-11","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT01237249","phase":"PHASE2","title":"Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2011-02","conditions":"Multiple Myeloma","enrollment":250},{"nctId":"NCT02471820","phase":"PHASE2","title":"Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Meletios A. Dimopoulos","startDate":"2014-11","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT00833833","phase":"PHASE1, PHASE2","title":"MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2008-06","conditions":"Multiple Myeloma","enrollment":259},{"nctId":"NCT01450215","phase":"PHASE2","title":"Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2011-03","conditions":"Multiple Myeloma","enrollment":62},{"nctId":"NCT01359657","phase":"PHASE1","title":"Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-09","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT01530594","phase":"PHASE3","title":"Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2009-01","conditions":"Multiple Myeloma","enrollment":440},{"nctId":"NCT00522392","phase":"PHASE3","title":"Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-09","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":48},{"nctId":"NCT00691704","phase":"PHASE2","title":"Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy","status":"COMPLETED","sponsor":"Cristina Gasparetto","startDate":"2008-08","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT00617591","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2008-01","conditions":"Multiple Myeloma","enrollment":57},{"nctId":"NCT01686386","phase":"PHASE1, PHASE2","title":"Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma","status":"UNKNOWN","sponsor":"Gruppo Italiano Studio Linfomi","startDate":"2010-02","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT01010243","phase":"PHASE1, PHASE2","title":"Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial","status":"UNKNOWN","sponsor":"University of Regensburg","startDate":"2009-10","conditions":"Multiple Myeloma","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":167,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Revlimid"],"phase":"phase_3","status":"active","brandName":"Lenalidomide and low-dose dexamethasone","genericName":"Lenalidomide and low-dose dexamethasone","companyName":"Celgene","companyId":"celgene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenalidomide enhances immune cell activity and has anti-angiogenic and anti-proliferative effects, while dexamethasone provides anti-inflammatory and immunosuppressive activity to reduce myeloma cell growth. Used for Multiple myeloma (newly diagnosed and relapsed/refractory), Light chain myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}